Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. (EMMA) Revenue
Annual & quarterly revenue history · segment & region breakdown
EMMA · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsEmmaus Life Sciences, Inc. trailing twelve-month (TTM) revenue is $0.01B, a decrease of 25.22% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | -$0.00B | -25.22% |
| 2024-12-31 | $0.02B | -$0.01B | -43.73% |
| 2023-12-31 | $0.03B | +$0.01B | +60.94% |
| 2022-12-31 | $0.02B | -$0.00B | -10.77% |
| 2021-12-31 | $0.02B | -$0.00B | -11.04% |
| 2020-12-31 | $0.02B | +$0.00B | +1.82% |
| 2019-12-31 | $0.02B | +$0.02B | +1628.88% |
| 2018-09-30 | $0.00B | +$0.00B | +924.12% |
| 2017-09-30 | $0.00B | +$0.00B | +51.00% |
| 2016-09-30 | $0.00B | -$0.00B | -14.99% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Emmaus Life Sciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Emmaus Life Sciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Emmaus Life Sciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EMMA revenue · 4 questionsEMMA's trailing twelve-month (TTM) revenue is $0.01B. That is a decrease of 25.22% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Emmaus Life Sciences, Inc. SEC filings · GAAP · Emmaus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026